Modality
Peptide
MOA
Anti-Tau
Target
JAK2
Pathway
Checkpoint
NASH
Development Pipeline
Preclinical
~Apr 2014
→ ~Jul 2015
Phase 1
~Oct 2015
→ ~Jan 2017
Phase 2
Apr 2017
→ Feb 2028
Phase 2Current
NCT04195036
2,768 pts·NASH
2017-04→2028-02·Terminated
2,768 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-02-061.9y awayPh3 Readout· NASH
Trial Timeline
Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2
P2/3
Termina…
Catalysts
Ph3 Readout
2028-02-06 · 1.9y away
NASH
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04195036 | Phase 2/3 | NASH | Terminated | 2768 | HAM-D |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| RHH-7558 | Roche | Phase 1 | SGLT2 | |
| NVS-5439 | Novartis | Preclinical | BET | |
| NVO-9630 | Novo Nordisk | Phase 2 | CD3 | |
| REG-2172 | Regeneron | Phase 1/2 | PCSK9 | |
| BGN-3305 | BeiGene | Phase 2 | BCMA | |
| GMA-5010 | Genmab | Phase 3 | JAK2 | |
| Sovarasimod | Halozyme | Phase 1/2 | WEE1 | |
| Teravorutinib | Illumina | Phase 2 | JAK2 | |
| Voxamavacamten | Corcept | Approved | BET | |
| AXS-4984 | Axsome | Preclinical | JAK2 |